RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Treatment of high alcohol consumption in a novel minipig model of alcohol use disorder
Liu, X., Panthagani, P., Gutierrez, A. G., Vega, A., Shaik, A. A., Aguilera, M. G., Sanchez, J. N., Willms, J. O., Backus, B., Blough, B., Pauli, E., Reid, T. W., Benton, T., Bailoo, J. D., & Bergeson, S. E. (2024). A pilot study: Treatment of high alcohol consumption in a novel minipig model of alcohol use disorder. Alcoholism Treatment Quarterly, 42(4), 393-403. https://doi.org/10.1080/07347324.2024.2355931
Three medications are FDA approved in the US for treatment of Alcohol Use Disorder (AUD), and a few others are used off-label. Patient compliance and efficacy in the broader population are major hurdles for current AUD medications. As a consequence, there is an urgent need for improved pharmacotherapeutics to complement behavioral approaches. Here, we report pilot testing of a minocycline analog, 10-butylether minocycline (BEM, 10 mg/kg p.o.), in two female minipigs with free-choice drinking to intoxication for nearly two and a half years. Each pig met DSM-5 criteria for diagnosis of severe AUD, and BEM reduced both alcohol intake and preference. BEM is currently undergoing testing for approval as an Investigational New Drug by the FDA for AUD treatment.
